A closer look at an Rx eye drop that can help break the cycle of inflammation in dry eye disease (DED)1
A closer look at an Rx eye drop that can help break the cycle of inflammation in dry eye disease (DED)1
A closer look:
~38 million people in the United States are living with DED2,3
76% of ECPs
reported an increase in patients between the ages of 18 and 34
with DED symptoms compared with 10 years ago4
ECP, eye care provider.
DED is a vicious cycle with many possible entry points5,6
Clinically significant inflammation is present in up to 65% of DED cases.9
A closer look:
Xiidra is uniquely designed to inhibit inflammation1
Xiidra can help inhibit T-cell activation and migration and may curb inflammatory cytokines to deliver precise action in dry eye disease1*
*Based on in vitro data. The exact mechanism of action of lifitegrast in DED is not known.
A closer look:
Xiidra was shown to provide symptom relief in as early as 2 weeks in clinical trials1,10
Four clinical trials assessed improvement in signs (measured by ICSS) and symptoms (measured by EDS/VR-OSDI) of DED (N=2,133)
Less artificial tear use reported by participants on lifitegrast vs vehicle from 3 to 12 months
EDS, eye dryness score; ICSS, inferior corneal fluorescein staining score; VR-OSDI, vision-related ocular surface disease index.
A closer look:
Xiidra was well tolerated in clinical trials
Across 5 clinical studies, most common adverse reactions (reported in 5% to 25% of patients)1:
Among lifitegrast-treated participants in a 1-year safety study & a pooled analysis of four 12-week studies11
<2%
discontinued due to dysgeusia
≤1%
discontinued due to instillation site irritation or pain
<2%
discontinued due to instillation site irritation reaction
Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
XIIDRA® (perfluorohexyloctane ophthalmic solution) 5% is indicated for the treatment of the signs and symptoms of dry eye disease (DED).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Click here for full Prescribing Information.
References:
1. XIIDRA. Prescribing information. Bausch & Lomb, Inc. 2. Paulsen AJ, Cruickshanks KJ, Fischer ME, et al. Dry eye in the Beaver Dam Offspring Study: prevalence, risk factors, and health-related quality of life. Am J Ophthalmol. 2014;157:799-806. 3. US population by age and gender, 2020. 4. Modern technology and a multi-screen lifestyle viewed as important factors in rising prevalence of dry eye disease. News release. PR Newswire; October 17, 2016. Accessed June 18, 2024. https://www.multivu.com/players/English/7893551-shire-dry-eye-disease-awareness/#:~:text=Shire%20plc%20(LSE%3A%20SHP%2C,eye%20disease%2C%20and%20that%20the 5. Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438-510. 6. Galor A, Britten-Jones AC, Feng Y, et al. TFOS lifestyle: impact of lifestyle challenges on the ocular surface. Ocul Surf. 2023;28:262-303. 7. Pflugfelder SC, de Paiva CS. The pathophysiology of dry eye disease: what we know and future directions for research. Ophthalmology. 2017;124(11S):S4-S13. 8. Zhang R, Pandzic E, Park M, Wakefield D, di Girolamo N. Inducing dry eye disease using a custom engineered desiccation system: impact on the ocular surface including keratin-14-positive limbal epithelial stem cells. Ocul Surf. 2021;21:145-159. 9. Sambursky R. Presence or absence of ocular surface inflammation directs clinical and therapeutic management of dry eye. Clin Ophthalmol. 2016;10:2337-2343. 10. Donnenfeld ED, Karpeck PM, Majmuder PA, et al. Safety of liļ¬tegrast ophthalmic solution 5.0% in patients with dry eye disease: a 1-year, multicenter, randomized, placebo-controlled study. Cornea. 2016;35(6):741-748. 11. Nichols KK, Donnenfeld ED, Karpecki PM, et al. Safety and tolerability of lifitegrast ophthalmic solution 5.0%: pooled analysis of five randomized controlled trials in dry eye disease. Eur J Ophthal. 2019;29(4):394-401.
XIIDRA® (perfluorohexyloctane ophthalmic solution) 5% is indicated for the treatment of the signs and symptoms of dry eye disease (DED).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Click here for full Prescribing Information.
